Cyclacel Pharma (CYCC) Prices 1.807M Share Common Offering at $7/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
After-Hours Stock Movers 03/11: (CFRX) (NVAX) (FNKO) Higher; (MRKR) (POSH) (ULTA) Lower (more...)
March 11, 2021 5:37 PM ESTToday's After-Hours Stock Movers
ContraFect Corporation (Nasdaq: CFRX) 36.2% HIGHER; has been awarded a cost-share contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). Under the terms of the contract, the Company will receive $9.8 million in initial funding and up to an additional $77.0 million. The initial funding will be used to support ContraFects ongoing pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial)... More
Cyclacel Pharmaceuticals (CYCC) to Offer Common Stock
March 11, 2021 4:01 PM ESTCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced today that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15%... More
